Septerna (NASDAQ:SEPN) Insider Samira Shaikhly Sells 2,178 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 2,178 shares of Septerna stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $35.18, for a total value of $76,622.04. Following the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $27,897.74. This represents a 73.31% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Samira Shaikhly also recently made the following trade(s):

• On Friday, June 12th, Samira Shaikhly sold 6,250 shares of Septerna stock. The stock was sold at an average price of $35.08, for a total value of $219,250.00.
• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The shares were sold at an average price of $28.93, for a total value of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88.

Septerna Trading Down 3.6%

SEPN opened at $33.49 on Wednesday. Septerna, Inc. has a 12-month low of $10.30 and a 12-month high of $37.99. The firm has a market capitalization of $1.51 billion, a PE ratio of -41.35 and a beta of 2.39. The firm has a 50 day moving average of $29.58 and a two-hundred day moving average of $27.49.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The business had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, analysts predict that Septerna, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Septerna

Hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in Septerna by 86.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after purchasing an additional 1,260,409 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Septerna during the 1st quarter worth approximately $21,334,000. First Light Asset Management LLC acquired a new position in shares of Septerna during the 4th quarter worth approximately $17,308,000. Primecap Management Co. CA purchased a new position in shares of Septerna during the 4th quarter valued at approximately $15,225,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Septerna during the 2nd quarter valued at approximately $5,723,000.

Analysts Set New Price Targets

SEPN has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Septerna in a research note on Wednesday, May 13th. Raymond James Financial upped their target price on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research note on Monday, June 8th. Stifel Nicolaus started coverage on Septerna in a report on Friday, May 1st. They set a “buy” rating and a $43.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $60.00 price target on shares of Septerna in a research report on Tuesday, March 10th. Finally, Truist Financial boosted their price target on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $45.78.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.